12 Health Care Stocks Moving In Wednesday's After-Market Session

Veeva Systems
Alps Group Inc
Omada Health, Inc.
DataMeds AI, Inc.
Intensity Therapeutics, Inc.

Veeva Systems

VEEV

0.00

Alps Group Inc

ALPS

0.00

Omada Health, Inc.

OMDA

0.00

DataMeds AI, Inc.

MEDS

0.00

Intensity Therapeutics, Inc.

INTS

0.00

Gainers

  • Veeva Systems (NYSE:VEEV) shares increased by 8.7% to $266.15 during Wednesday's after-market session. The market value of their outstanding shares is at $40.0 billion. The company's, Q2 earnings came out today.
  • ALPS Group (NASDAQ:ALPS) stock rose 8.17% to $0.43. The market value of their outstanding shares is at $52.3 million.
  • Omada Health (NASDAQ:OMDA) shares moved upwards by 6.84% to $25.6. The market value of their outstanding shares is at $1.4 billion.
  • DataMEDS AI (NASDAQ:MEDS) shares rose 6.36% to $1.42. The company's market cap stands at $4.1 million.
  • Intensity Therapeutics (NASDAQ:INTS) shares moved upwards by 5.29% to $4.77. The market value of their outstanding shares is at $15.9 million.
  • NewGenIvf Group (NASDAQ:NIVF) stock moved upwards by 5.28% to $0.5. The company's market cap stands at $3.5 million.

Losers

  • ENDRA Life Sciences (NASDAQ:NDRA) stock declined by 6.8% to $5.07 during Wednesday's after-market session. The market value of their outstanding shares is at $7.1 million.
  • HeartSciences (NASDAQ:HSCS) shares fell 6.03% to $2.81. The market value of their outstanding shares is at $12.9 million.
  • XORTX Therapeutics (NASDAQ:XRTX) shares decreased by 5.16% to $2.21. The market value of their outstanding shares is at $4.1 million.
  • Bone Biologics (NASDAQ:BBLG) stock fell 4.23% to $0.59. The market value of their outstanding shares is at $1.6 million.
  • Celularity (NASDAQ:CELU) shares fell 3.46% to $0.85. The company's market cap stands at $22.8 million.
  • Liminatus Pharma (NASDAQ:LIMN) shares fell 3.18% to $4.27. The market value of their outstanding shares is at $6.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.